This post was written by Paul Sheives. FDA has announced plans to develop guidance and the opening of a public docket for public comment on the co-development of two or more drugs to be used in combination to treat a single disease or condition. FDA seeks comment on general methodological and regulatory issues that arise in the co-development of two or more drugs to treat the same condition, including in scenarios: (1) where the drugs are intended to treat different symptoms of the same disease or condition, (2) where one drug is intended to increase the effectiveness of the other; and (3) for specific therapeutic categories, including oncology, anti-infectives, seizure disorders, cardiovascular diseases, and any other relevant categories. Comments are being accepted until September 7, 2010.